Target intelligence / Profile preview

Solute carrier family 1 member 5 (SLC1A5) (SLC1A5)

Target
SLC1A5
Molecular classification
Transporter, Solute carrier family
01

Overview

Solute carrier family 1 member 5 (SLC1A5), also known as ASCT2, is a sodium-dependent neutral amino acid transporter that primarily mediates the uptake of glutamine, a conditionally essential nutrient for rapidly proliferating cells [5, 14]. In many cancers, SLC1A5 is significantly upregulated to support "glutamine addiction," where it fuels the tricarboxylic acid (TCA) cycle and activates the mTORC1 pathway to drive tumor growth and survival [9, 15]. Beyond its role in tumor cells, SLC1A5 is critical for the metabolic reprogramming and activation of Natural Killer (NK) cells and T cells, particularly following cytokine stimulation with IL-2 or IL-15 [4, 8]. While pharmacological inhibition of SLC1A5 with small molecules like V-9302 is a promising strategy to starve tumor cells and induce apoptosis or ferroptosis, it presents a therapeutic challenge because it may simultaneously impair the anti-tumor activity of immune cells within the tumor microenvironment [15, 16]. Consequently, SLC1A5 represents a complex target where the benefits of metabolic starvation of the tumor must be balanced against the potential for unintended immunosuppression [4, 20].

Other names
Alanine-serine-cysteine transporter 2ASCT2ATB(0)Neutral amino acid transporter ASCT2M7V1RDRCAAAT
02

Mechanism of action

Competitive inhibition of sodium-dependent neutral amino acid transport, primarily blocking glutamine uptake to suppress glutaminolysis and mTORC1 signaling.

03

Biological functions

Amino acid transportCell proliferationImmune responseMetabolic reprogrammingApoptosisFerroptosisSignal transduction
04

Disease associations

CancerInfection
05

Safety considerations

Suppression of NK cell and T cell activation and effector functions (e.g., IFN-gamma production)Potential toxicity to normal tissues with high glutamine demand, such as the intestinal epitheliumCompensatory upregulation of alternative transporters like SNAT1 or SNAT2Impairment of systemic immune surveillance
06

Interacting drugs

V-9302

3 more in the full profile.

07

Biomarkers

SLC1A5 mRNA expressionSLC1A5 protein levels (IHC)Intracellular glutamine levelsc-Myc expressionmTORC1 activity (p-S6K1)Ferroptosis markers (e.g., lipid peroxidation)

Beyond the preview

Go deeper on Solute carrier family 1 member 5 (SLC1A5) (SLC1A5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 1 member 5 (SLC1A5) (SLC1A5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call